MannKind Corp (NASDAQ:MNKD)

Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
biotech

Rising Short Interest in Biotech Stocks

The short interest data is out for the August 15 settlement date. Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts, ...
Read Full Story »
Stock Split Image

What the Market is Telling MannKind (Updated)

MannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week's news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has ...
Read Full Story »
76764023

MannKind Secures Future of Afrezza in Major Sanofi Deal

MannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin ...
Read Full Story »
buy sell

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

Stocks hit a new all-time this last week on the heels of a strong unemployment and jobs number. Now investors have to decide whether the next year or more will ...
Read Full Story »
MannKind Poll smaller

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

MannKind Corp. (NASDAQ: MNKD) has dipped back under $10 in the wake of the FDA finally giving approval for its Afrezza as inhalable insulin for diabetic patients. The move may ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

Stocks were firm on Tuesday morning during a shortened week that will be full of economic reports. 24/7 Wall St. reviews dozens of analyst research reports each morning of the ...
Read Full Story »
76764023

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

MannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 ...
Read Full Story »
biotech

Vindication for MannKind on FDA Approval

After markets closed last Friday, MannKind Corp. (NASDAQ: MNKD) announced that the U.S. Food and Drug Administration (FDA) had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control ...
Read Full Story »
biotech

MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval

The U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with diabetes. The ...
Read Full Story »
buy sell

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

Stocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the ...
Read Full Story »
76764023

The MannKind Lifeline Lights Up

MannKind Corp. (NASDAQ: MNKD) could have been and should have been featured in our Analyst Stocks to Buy Under $10 For Huge Upside this weekend, but MannKind is such a ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Alcoa, Intel, Lululemon, MannKind, Marathon, Occidental and More

It is Friday (the 13th, mind you) and stocks are trying to find direction after a couple of big selling days this week. Investors keep hearing that the raging bull market ...
Read Full Story »
biotech

Short Sellers Remain Vigilant Against Top Biotech Stocks

Short sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company ...
Read Full Story »
ten bucks

Twelve Analyst Stocks to Buy Under $10 for Big Upside

Stocks hit new highs this past week, only to sell off handily. Investors want gains, but they remain wary. 24/7 Wall St. reviews dozens of analyst research reports from Wall ...
Read Full Story »